Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: A randomized trial

Journal of Viral Hepatitis

Volumn 23, Issue 2, 2016, Pages 80-88

  Lagging, M ^a   Brown, A ^b   Mantry, P S ^c   Ramji, A ^d   Weilert, F ^e   Vierling, J M ^f   Howe, A ^g   Gendrano, I N ^g   Hwang, P ^g   Zhang, B ^g   Wahl, J ^g   Robertson, M ^g   Mobashery, N ^g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ST MARY S HOSPITAL   (United Kingdom)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

adverse event; clinical trial; direct acting antiviral drugs; resistance; sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; GRAZOPREVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; MK-5172; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A PROTEIN, FLAVIVIRUS; PEGINTERFERON ALPHA2A; QUINOXALINE DERIVATIVE; RECOMBINANT PROTEIN; VIRAL PROTEIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; CHILL; CHRONIC HEPATITIS C; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INJECTION SITE ERYTHEMA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUINOXALINES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84955721843     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12464     Document Type: Article

References (14)

1. Bacon B, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
2. Poordad F, McCone J, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
5. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
6. Fried MW, Buti M, Dore GJ, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
7. Summa V, Ludmerer SW, McCauley JA, et al,. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56: 4161-4167.
8. Manns M, Vierling JM, Bacon BR, et al,. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014; 147: 366-376.
9. American Association for the Study of Liver Diseases, Infectious Disease Society of North America. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. AASLD/IDSA Web Site. Available at: http://www.hcvguidelines.org. Accessed August 27, 2015.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
11. Lawitz E, Gane E, Pearlman B, et al,. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; 385: 1075-1086.
12. Zeuzem S, Ghalib R, Reddy KR, et al,. Grazoprevir-Elbasvir Combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163: 1-13.
13. Forns X, Gordon SC, Zuckerman E, et al,. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63: 564-72.
14. Yeh WW, Fraser IP, Reitmann C, et al,. Pharmacokinetic interaction of HCV protease inhibitor MK-5172 and ritonavir in healthy subjects. Global Antivir J 2013; 9 (Suppl. 2): 55-56 [abstract].